Longitude Capital
Growth to Late venture capital firm · Menlo Park
Longitude Capital is a Growth to Late venture capital firm based in Menlo Park that invests in Biotechnology, Medical Technology and Health Solutions. DryPowder has no SEC Form D on file for Longitude Capital as of June 3, 2026. Partners at Longitude Capital include Juliet Bakker (Managing Director, Founder) and Maxwell Bikoff (Managing Director).
Updated · Sources: fund website
- Stages
- Growth–Late
- Headquarters
- Menlo Park
Overview
Longitude Capital at a glance
- Stage
- Growth, Clinical, Commercial, Late
- Sectors
- Biotechnology, Medical Technology, Health Solutions, Diagnostics, Surgical Devices, Therapeutics
- Headquarters
- Menlo Park
- Cold inbound
- Warm intro preferred
- Website
- longitudecapital.com
Investment thesis
Longitude Capital invests in transformative healthcare companies—biotechnology, medical technology, and health solutions—that improve clinical outcomes, enhance patient quality of life, and reduce cost of care through venture growth investments in clinically de-risked, commercially-staged assets.
Stated on longitudecapital.comWEBSITE
What sets Longitude Capital apart
- 200+ years combined life sciences investing experience across team
- 18+ year track record since 2006 with $2B+ deployed across six funds
- Dual-office structure (Menlo Park, Boston) providing coast-to-coast medtech/biotech coverage
- Executive operating experience embedded (Roche, Novartis, Cardinal Health, GRAIL CFO, Jazz CFO)
Recent investments
DryPowder has tracked these recent investments from Longitude Capital: CG Oncology (CGON), Alpha-9 Oncology, OrsoBio and Aviceda Therapeutics.
What the portfolio shows
Portfolio 64
Backed: Bolt Medical, Ceribell (CBLL), Endogenex + 61 more
Partners
6 partners at Longitude Capital
- Juliet Bakker
Managing Director, Founder
- Maxwell Bikoff
Managing Director
- Patrick Enright
Managing Director, Founder
- Carolyn Helms
Managing Director, Chief Financial Officer
- Brian Liu
Managing Director
- Matthew Young
Managing Director
From the fund's website. Contact details not yet verified.
Similar funds
Funds like Longitude Capital
Investor lists that include Longitude Capital
FAQ
Questions about Longitude Capital
What does Longitude Capital invest in?
Longitude Capital is a Clinical, Commercial, Growth, Late stage Biotechnology, Medical technology, Health solutions, Diagnostics, Surgical devices, Therapeutics investor, primarily investing in US. Their thesis: Longitude Capital invests in transformative healthcare companies—biotechnology, medical technology, and health solutions—that improve clinical outcomes, enhance patient quality of life, and reduce cost of care through venture growth investments in clinically de-risked, commercially-staged assets.
What makes Longitude Capital different from other funds?
Longitude Capital stands out on 4 points: 200+ years combined life sciences investing experience across team; 18+ year track record since 2006 with $2B+ deployed across six funds; Dual-office structure (Menlo Park, Boston) providing coast-to-coast medtech/biotech coverage; Executive operating experience embedded (Roche, Novartis, Cardinal Health, GRAIL CFO, Jazz CFO).
What has Longitude Capital invested in recently?
Recent investments DryPowder has tracked from Longitude Capital include CG Oncology (CGON), Alpha-9 Oncology, OrsoBio, Aviceda Therapeutics.
How do I reach Longitude Capital?
Longitude Capital does not generally take cold inbound; a warm introduction from a founder or investor the firm knows is the usual path.
Sources
Updated